Estudio de seguridad, tolerabilidad y resultados clínicos de Egaten en pacientes con fascioliasis (6 años de edad o mayores).
Un estudio abierto, multicéntrico y de fase IV para determinar la seguridad, la tolerabilidad y los resultados clínicos después de la administración oral de EGATEN™ (triclabendazol) en pacientes (6 años de edad o más) con fascioliasis.
The study evaluated safety and tolerability along with clinical outcomes of Egaten administered as per the FDA approved dosing regimen of 2 doses of 10 mg/kg (given approximately 12 hours apart) in Fascioliasis participants (≥ 6 years of age).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This was an open-label, single-arm, multi-center multi-country, non-comparative study planned in adult and pediatric participants (≥ 6 years of age) with acute or chronic fascioliasis.
Screening/Baseline: Screening and baseline assessments were performed as per protocol.
Treatment phase: Enrolled participants were treated with two doses of 10 mg/kg triclabendazole given approximately 12 hours apart, with the first dose administered on Day 1 under site study team's supervision. The second dose was either taken at home (self-administered) or administered at the site.
Follow-up phase: Post-treatment at Day 3 and Day 6, the enrolled participants were followed for safety and tolerability. These visits were conducted by telephone, through home visits by qualified personnel, or through onsite visits, based on the investigator's discretion. During the post treatment study site visits at Day 10, Day 30, Day 60, and Day 90 (EOS visit), the enrolled participants were followed for safety, tolerability, and efficacy. On Day 15, Day 45, and Day 75, telephonic follow ups (primarily for safety) were conducted.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050010
- Novartis Investigative Site
-
-
-
-
-
Alexandria, Egipto, 21131
- Novartis Investigative Site
-
-
Egypt
-
Cairo, Egypt, Egipto, 11617
- Novartis Investigative Site
-
-
-
-
-
Cusco, Perú, 08002
- Novartis Investigative Site
-
-
Lima region
-
San Martín de Porres, Lima region, Perú, 15102
- Novartis Investigative Site
-
-
-
-
-
Sur, Turquía (Türkiye), 21280
- Novartis Investigative Site
-
Van, Turquía (Türkiye), 65080
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Turquía (Türkiye), 34093
- Novartis Investigative Site
-
-
Sehitkamil
-
Gaziantep, Sehitkamil, Turquía (Türkiye), 27310
- Novartis Investigative Site
-
-
-
-
Binh Dinh
-
Qui Nhon, Binh Dinh, Vietnam, 590000
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Written informed consent must be obtained before any study protocol specific assessment is performed.
- Parental/legal guardian informed consent must be obtained and signed for pediatric subjects prior to any study related procedure.
- Subjects < 18 years old, who are capable of providing assent, must provide assent with parental/legal guardian consent or as per local ethical guidelines.
- If the subject is unable to read and write or otherwise incapable of signing an informed consent, then a witnessed consent according to local ethical standards is permitted.
-
Subjects (Adult and pediatric subjects ≥ 6 years of age and above 12.5 kg of weight) at time of consenting must have been diagnosed with fascioliasis based on clinical signs, symptoms and laboratory evaluations as per local clinical practice.
Exclusion Criteria:
-
Subjects diagnosed with ectopic fascioliasis, extrahepatic involvement (e.g., lungs, spleen, pancreas, subcutaneous tissue, gastrointestinal organs, etc.).
-
Subjects with known hypersensitivity to triclabendazole /other benzimidazole derivatives and/or any of the excipients in Egaten.
-
Subjects taking any anthelmintic medications within two weeks or 5 half-lives, whichever is longer prior to enrolling into study.
-
Inability or unwillingness to undergo study related procedures.
-
Subjects who in the judgment of the Clinical Investigator are unsuitable for the trial or who have to be excluded in order to be compliant with local fascioliasis management guidelines that may differ from the FDA approved label, including but not limited to :
- Subjects who are machine operators or drivers.
- Medical history of liver (other than fascioliasis), kidney or cardiac disease.
-
Females (including under the age of 18) known to be pregnant or testing positive for pregnancy at screening.
-
Lactating women unwilling to discontinue lactation up to 72 hours after the second dose administration or as per local guidelines.
-
Subjects requiring therapeutic drug monitoring of CYP2C19 substrate(s) (e.g. S-mephenytoin).
-
Subjects with medical history of QT prolongation or a history of symptoms compatible with a long QT interval or on medication which prolong the QT interval.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Egaten
Triclabendazole was administered as two 10 mg/kg doses given approximately 12 hours apart. Both doses were administered orally with food. |
Egaten 250 mg scored tablets for oral use.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Adverse events were reported from the first dose of study treatment until approximately 90 days thereafter.
|
Number of participants with treatment emergent adverse events (any AE regardless of seriousness), and SAEs. |
Adverse events were reported from the first dose of study treatment until approximately 90 days thereafter.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Acute and Chronic Fascioliasis Participants Who Achieved Clinical Response
Periodo de tiempo: Baseline, Day 10
|
Clinical Response at Day 10 was defined as improvement or resolution of baseline signs and symptoms. 95% confidence interval (CI) is calculated based on Clopper-Pearson method. |
Baseline, Day 10
|
|
Percentage of Acute Fascioliasis Participants Who Achieved Clinical Cure
Periodo de tiempo: Baseline, Day 30, Day 60 and Day 90
|
A participant was considered to achieve clinical cure if all of the following criteria were met.
Abdomen - for hepatic lesions and/or biliary tract blockage caused by Fasciola worm(s) • Improvement in the lab parameter from baseline: Eosinophil count: ≥ 50% reduction from baseline value or reaching normal range if baseline value was above normal range 95% confidence interval (CI) is calculated based on Clopper-Pearson method. |
Baseline, Day 30, Day 60 and Day 90
|
|
Percentage of Chronic Fascioliasis Participants Who Achieved Clinical Cure
Periodo de tiempo: Baseline, Day 30, Day 60 and Day 90
|
A participant was considered to achieve clinical cure if all of the following criteria were met.
Eosinophil count: ≥50% reduction from baseline or reaching normal range if baseline value was above normal range Hemoglobin: ≥1 g/dL increase from baseline value or reaching normal range if baseline value was below normal range Liver function test: ≥1 grade improvement from baseline or reaching normal range for each test if baseline value was above normal range Erythrocyte sedimentation rate: ≥ 50% reduction from baseline or reaching normal range if baseline value was above normal range 95% CI is calculated based on Clopper-Pearson method. |
Baseline, Day 30, Day 60 and Day 90
|
|
Percentage of Chronic Fascioliasis Participants Who Achieved Parasitological Cure
Periodo de tiempo: At Day 10, Day 30, Day 60 and Day 90
|
The parasitological cure rate in chronic fascioliasis participants was measured by the proportion of participants with absence of fasciola eggs confirmed by stool examination. In case of missing assessments at post baseline visits, parasitological cure is imputed as cured if two consecutive prior visits are negative, else parasitological cure is imputed as not cured. 95% confidence interval (CI) is calculated based on Clopper-Pearson method. |
At Day 10, Day 30, Day 60 and Day 90
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones
- Enfermedades del Sistema Digestivo
- Enfermedades del HIGADO
- Enfermedades parasitarias
- Helmintiasis
- Infecciones por trematodos
- Enfermedades Del Hígado Parasitarias
- Fascioliasis
- Compuestos heterocíclicos
- Benzimidazoles
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Triclabendazol
Otros números de identificación del estudio
- CEGA230B2404
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .